graph EGM comparisons
nivolumab alonetitlenivolumab plus SoCtitleplacebo plus SoCtitlepemetrexed plus platintitleStandard of Care (SoC)titledocetaxeltitleCheckMate 816, 2022 NCT02998528 locally advanced NSCLC - (neo)adjuvant (NA) 179/179CheckMate 227 (NC vs C ; PDL1<1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 negative 177/186CheckMate 026 (PDL1>1%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 271/270CheckMate 026 (PDL1>5%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 211/212CheckMate 078, 2019 NCT02613507 mNSCLC - L2 - all population 338/166CheckMate 057, 2015 NCT01673867 non squamous - mNSCLC - L2 - all population 292/290CheckMate 816, 2022 NCT02998528 NSCLC neoadjuvant setting 179/179CheckMate 017, 2015 NCT01642004 squamous - mNSCLC - L2 - all population 135/137

Pathology:  locally advanced NSCLC - (neo)adjuvant (NA);   mNSCLC - L1 - PDL1 negative;   mNSCLC - L1 - PDL1 positive;   mNSCLC - L2 - all population;   non squamous - mNSCLC - L2 - all population;   NSCLC neoadjuvant setting;   squamous - mNSCLC - L2 - all population; 

locally advanced NSCLC - (neo)adjuvant (NA)mNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivemNSCLC - L2 - all populationnon squamous - mNSCLC - L2 - all populationNSCLC neoadjuvant settingsquamous - mNSCLC - L2 - all population
CheckMate 816, 2022CheckMate 227 (NC vs C ; PDL1<1%), 2018CheckMate 026 (PDL1>1%), 2016CheckMate 026 (PDL1>5%), 2016CheckMate 078, 2019CheckMate 057, 2015CheckMate 816, 2022CheckMate 017, 2015
nivolumab alone5T1T1T1T1T1
nivolumab plus SoC3T1T1T1
placebo plus SoC0T0T0
pemetrexed plus platin0T0
Standard of Care (SoC)0T0T0
docetaxel0T0T0T0